Multipel sklerose

Igangværende projekter

• ENSEMBLE (Open label study)
  An Open-Label Study to evaluate the efficacy and safety of Ocrelizumab in patients with early stage relapsing remitting multiple sclerosis. 
  
  
• CLARIFY inkl. Extemsionstudy (Observationsstudie)
  A 2-year Prospective Study to Assess Health-related Quality of Life in Subjects with Highly-Active Relapsing Multiple Sclerosis Treated with Mavenclad®
  
  
• HERKULES (RCT)
  A Phase 3, randomized, double-blind, efficacy and safety study comparing SAR442168 to placebo in participants with nonrelapsing secondary progressive multiple sclerosis (HERCULES)
  
  
• PERSEUS (RCT)
  A Phase 3, randomized, double-blind, efficacy and safety study comparing SAR442168 to placebo in participants with primary progressive multiple sclerosis (PERSEUS)
  
  
• GEMINI (RCT)
  A Phase 3, randomized, double-blind efficacy and safety study comparing SAR442168 to teriflunomide (Aubagio®) in participants with relapsing forms of multiple sclerosis (GEMINI 1)
  
  
• GAVOTTE (RCT)
  A Phase 3B multicenter, randomized, double-blind, controlled study to evaluate the efficacym safety and pharmacokinetics of a higher dose of Ocrelizumab in adults with primary progressive multiple sclerosis.
  
  
• EXIT 20 Covid 19 (Observationsstudie)
  Extended interval of anti-CD20 therapy and clinical outcomes in multiple sclerosis during COVID-19
  
  
• FENHANCE (RCT)
  A phase 3 multicenter, randomized, double-blind, double-dummy, parallel-group study to evaluate the efficacy and safety of Fenebrutinib compared with Teriflunomide in adult patients with relapsing multiple sclerosis.
  
  
• PASS (Post authorization safety study)
  A prospective, multicenter, observational post-authorization safety study to avaluate the long term safety profile of Lemtrada® (Alemtuzumab) treatment in patients with relapsing forms of multiple sclerosis. 
  
  
• Cannabis-studie (RCT)
  Effekten af medicinsk cannabis på neuropatiske smerter og spasticitet hos patienter med MS og patienter med rygmarvsskade. 
  
  
• DanNORMS (RCT)
  Danish non-inferiority study of ocrelizumab and rituximab in MS (DanNORMS): A randomized study comparing the efficacy of ocrelizumab and rituximab in active multiple sclerosis. 

Medarbejdere

Læger

• Overlæge, PhD klinisk lektor Claudia Hilt Kristensen
• Afdelingslæge Ismael Bazinjii
• Afdelingslæge Inga Urbonaviciute
• Reservelæge Victoria Hansen
• Reservelæge Jakob Schæfer

Sygeplejersker

• Projektsygeplejerske/klinisk koordinator Anne Hochheim Magnussen
• Projektsygeplejerske Inge Folden

Sekretær

• Ingerlise Rasmussen

Samarbejdspartnere

• Aalborg Universitet, især arbejdsgruppen omkring John Dirk Nieland
• Dansk multipel Sklerose register
• Medicinalindustrien – firmaer der producerer sklerosemedicin (Roche, Novartis, Biogen, Merck, Sanofi, Teva)
• Ph.d.-studerende i andre regioner, der vælger landsdækkende dataindsamling med alle MS-klinikker som deltagende.

Udvalgte publikationer

2020

• Acute onset psychosis and cognitive impairment as primary manifestation in Relapsing Remitting Multiple Sclerosis
  Nandy, A., Nielsen, M., Hilt, C. C., Mogensen, P. & Yavarian, Y., 2020.
  Publikation: Konferencebidrag uden forlag/tidsskrift › Poster › Forskning › peer review
• Acute onset psychosis and cognitive impairment as primary manifestation in Relapsing Remitting Multiple Sclerosis
  Nandy, A., Nielsen, M., Hilt, C. C., Mogensen, P. & Yavarian, Y., 2020.
  Publikation: Konferencebidrag uden forlag/tidsskrift › Konferenceabstrakt til konference › Forskning › peer review
• A nationwide study of secondary progressive multiple sclerosis in the Danish population
  Magyari, M., Kopp, T. I., Bramow, S., Battisti, J. L. F., Hilt, C., Rasmussen, P. V. & Sellebjerg, F., 14 apr. 2020, I : Neurology. 94, 15, Supplement, s. 2083
  Publikation: Bidrag til tidsskrift › Konferenceabstrakt i tidsskrift › Forskning › peer review

2019 

• A Danish nationwide pharmacoepidemiological study of treatment with teriflumonide
  Magyari, M., Pfleger, C. H., Joensen, H., Kopp, T. I., Illes, Z., Sorensen, P. S. & Sellebjerg, F., 2019, I : Multiple Sclerosis Journal. 25, Suppl. 2, s. 292 1 s., P609.
  Publikation: Bidrag til tidsskrift › Konferenceabstrakt i tidsskrift › Forskning › peer review
• Benefit–risk Assessment of Cladribine Using Multi-criteria Decision Analysis (MCDA) for Patients With Relapsing-remitting Multiple Sclerosis
  Vermersch, P., Martinelli, V., Pfleger, C., Rieckmann, P., Alonso-Magdalena, L., Galazka, A., Dangond, F. & Phillips, L., feb. 2019, I : Clinical Therapeutics. 41, 2, s. 249-260.e18
  Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review
• Incidence and risk of malignancies by type, in multiple sclerosis (MS) patients, compared from the Netherlands (NL) and Denmark (DK)
  Nørgaard, M., Foch, C., Kuiper, J., Magyari, M., Veres, K., Overbeek, J., Sellebjerg, F., Pfleger, C., Frederiksen, J. L., Bountmy, E. & Sabidó, M., 2019, I : European Journal of Neurology. 26, Suppl. 1, s. 681 1 s., EPO2226.
  Publikation: Bidrag til tidsskrift › Konferenceabstrakt i tidsskrift › Forskning › peer review
• Macular oedema and changes in macular thickness in multiple sclerosis patients treated with fingolimod
  Nørgaard, T. L., Andersen, C. U., Hilt, C. & Andersen, C. U., 26 dec. 2019, I : Basic & Clinical Pharmacology & Toxicology.
  Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review
• Objective smartphone vision tests to characterize visual function in multiple sclerosis patients with and without optic neuritis
  Zarei, K., David, S., Pfleger, C. C., Berman, D., Poolman, P., Ledolter, J. & Kardon, R., 1 sep. 2019, I : Multiple Sclerosis Journal. 25, Suppl. 2, s. 643-644 2 s., P1189.
  Publikation: Bidrag til tidsskrift › Konferenceabstrakt i tidsskrift › Forskning › peer review